NEW YORK (GenomeWeb) – Accelerate Diagnostics' first quarter revenues dropped 13 percent year over year, the company said in a regulatory document on Friday.

In a Form 10-Q filed with the US Securities and Exchange Commission, the Tucson, Ariz.-based firm reported revenues of $14,000 for the three months ended March 31, compared to $16,000 in the year-ago quarter. Revenues for both quarters derived from licensing and royalty revenues.

The drop resulted from fluctuations in partner sales volumes, which affected Accelerate, it said in its SEC document.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.